ApoPharma has decided to several post-marketing necessity and commitments. One commitment includes additional study of the usage of Ferriprox in individuals with sickle cell disease who have transfusional iron overload. Earlier this full year, the U.S. Division of Health and Human Solutions released the Sickle Cell Disease Initiative combining HHS agencies to improve the quality and level of SCD data, develop greatest practice suggestions and quality of caution metrics, improve health care coordination and delivery of look after patients with SCD, facilitate approval of new medical products, and expand research on SCD. Ferriprox is certainly marketed by ApoPharma Inc.CIGNA recognizes the enactment of Patient Security and Affordable Care Work CIGNA Corp. recognizes the historical significance of the enactment of the Patient Protection and Affordable Care Act. The statutory law will expand access to health insurance to numerous who currently do not have coverage. We will continue to work with employer partners to greatly help them and their employees navigate medical care system, manage their health risks and stretch their healthcare dollars further.